Zosano Pharma (ZSAN) & Alder BioPharmaceuticals (ALDR) Head to Head Analysis

Zosano Pharma (NASDAQ: ZSAN) and Alder BioPharmaceuticals (NASDAQ:ALDR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Institutional & Insider Ownership

19.4% of Zosano Pharma shares are owned by institutional investors. Comparatively, 96.8% of Alder BioPharmaceuticals shares are owned by institutional investors. 2.8% of Zosano Pharma shares are owned by company insiders. Comparatively, 10.6% of Alder BioPharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Zosano Pharma and Alder BioPharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zosano Pharma N/A -169.79% -94.28%
Alder BioPharmaceuticals N/A -93.14% -84.14%

Earnings & Valuation

This table compares Zosano Pharma and Alder BioPharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zosano Pharma $310,000.00 66.83 -$29.83 million ($1.18) -0.44
Alder BioPharmaceuticals $110,000.00 10,995.60 -$156.25 million ($5.37) -3.32

Zosano Pharma has higher revenue and earnings than Alder BioPharmaceuticals. Alder BioPharmaceuticals is trading at a lower price-to-earnings ratio than Zosano Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Zosano Pharma and Alder BioPharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zosano Pharma 0 0 2 0 3.00
Alder BioPharmaceuticals 0 1 11 0 2.92

Zosano Pharma presently has a consensus price target of $3.50, suggesting a potential upside of 566.67%. Alder BioPharmaceuticals has a consensus price target of $30.42, suggesting a potential upside of 70.40%. Given Zosano Pharma’s stronger consensus rating and higher possible upside, equities analysts clearly believe Zosano Pharma is more favorable than Alder BioPharmaceuticals.

About Zosano Pharma

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder’s third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply